Literature DB >> 11222667

Pronociceptive actions of dynorphin maintain chronic neuropathic pain.

Z Wang1, L R Gardell, M H Ossipov, T W Vanderah, M B Brennan, U Hochgeschwender, V J Hruby, T P Malan, J Lai, F Porreca.   

Abstract

Whereas tissue injury increases spinal dynorphin expression, the functional relevance of this upregulation to persistent pain is unknown. Here, mice lacking the prodynorphin gene were studied for sensitivity to non-noxious and noxious stimuli, before and after induction of experimental neuropathic pain. Prodynorphin knock-out (KO) mice had normal responses to acute non-noxious stimuli and a mild increased sensitivity to some noxious stimuli. After spinal nerve ligation (SNL), both wild-type (WT) and KO mice demonstrated decreased thresholds to innocuous mechanical and to noxious thermal stimuli, indicating that dynorphin is not required for initiation of neuropathic pain. However, whereas neuropathic pain was sustained in WT mice, KO mice showed a return to baselines by post-SNL day 10. In WT mice, SNL upregulated lumbar dynorphin content on day 10, but not day 2, after injury. Intrathecal dynorphin antiserum reversed neuropathic pain in WT mice at post-SNL day 10 (when dynorphin was upregulated) but not on post-SNL day 2; intrathecal MK-801 reversed SNL-pain at both times. Opioid (mu, delta, and kappa) receptor density and G-protein activation were not different between WT and KO mice and were unchanged by SNL injury. The observations suggest (1) an early, dynorphin-independent phase of neuropathic pain and a later dynorphin-dependent stage, (2) that upregulated spinal dynorphin is pronociceptive and required for the maintenance of persistent neuropathic pain, and (3) that processes required for the initiation and the maintenance of the neuropathic pain state are distinct. Identification of mechanisms that maintain neuropathic pain appears important for strategies to treat neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11222667      PMCID: PMC6762963     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  30 in total

1.  Spontaneous activity of axotomized afferent neurons after L5 spinal nerve injury in rats.

Authors:  X Liu; S Eschenfelder; K H Blenk; W Jänig; H Häbler
Journal:  Pain       Date:  2000-02       Impact factor: 6.961

2.  Spinally administered dynorphin A produces long-lasting allodynia: involvement of NMDA but not opioid receptors.

Authors:  T M Laughlin; T W Vanderah; J Lashbrook; M L Nichols; M Ossipov; F Porreca; G L Wilcox
Journal:  Pain       Date:  1997-08       Impact factor: 6.961

3.  Dynorphin-(1-13), an extraordinarily potent opioid peptide.

Authors:  A Goldstein; S Tachibana; L I Lowney; M Hunkapiller; L Hood
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

4.  Generation of dynorphin knockout mice.

Authors:  N Sharifi; N Diehl; L Yaswen; M B Brennan; U Hochgeschwender
Journal:  Brain Res Mol Brain Res       Date:  2001-01-31

5.  Differential activation of spinal cord dynorphin and enkephalin neurons during hyperalgesia: evidence using cDNA hybridization.

Authors:  M J Iadarola; J Douglass; O Civelli; J R Naranjo
Journal:  Brain Res       Date:  1988-07-12       Impact factor: 3.252

6.  Tactile allodynia in the absence of C-fiber activation: altered firing properties of DRG neurons following spinal nerve injury.

Authors:  Chang-Ning Liu; Patrick D Wall; Efrat Ben-Dor; Martin Michaelis; Ron Amir; Marshall Devor
Journal:  Pain       Date:  2000-04       Impact factor: 6.961

Review 7.  Neurotoxic versus neuroprotective actions of endogenous opioid peptides: implications for treatment of CNS injury.

Authors:  A I Faden
Journal:  NIDA Res Monogr       Date:  1996

8.  Quantitative assessment of tactile allodynia in the rat paw.

Authors:  S R Chaplan; F W Bach; J W Pogrel; J M Chung; T L Yaksh
Journal:  J Neurosci Methods       Date:  1994-07       Impact factor: 2.390

9.  Characterization of the antiallodynic efficacy of morphine in a model of neuropathic pain in rats.

Authors:  D Bian; M L Nichols; M H Ossipov; J Lai; F Porreca
Journal:  Neuroreport       Date:  1995-10-23       Impact factor: 1.837

10.  Dynorphin uses a non-opioid mechanism to potentiate N-methyl-D-aspartate currents in single rat periaqueductal gray neurons.

Authors:  S L Lai; Y Gu; L Y Huang
Journal:  Neurosci Lett       Date:  1998-05-15       Impact factor: 3.046

View more
  87 in total

Review 1.  Dynorphin A analogs for the treatment of chronic neuropathic pain.

Authors:  Sara M Hall; Yeon Sun Lee; Victor J Hruby
Journal:  Future Med Chem       Date:  2016-01-29       Impact factor: 3.808

2.  Control of chronic pain by the ubiquitin proteasome system in the spinal cord.

Authors:  Michael H Ossipov; Igor Bazov; Luis R Gardell; Justin Kowal; Tatiana Yakovleva; Ivan Usynin; Tomas J Ekström; Frank Porreca; Georgy Bakalkin
Journal:  J Neurosci       Date:  2007-08-01       Impact factor: 6.167

3.  Effect of adenoviral delivery of prodynorphin gene on experimental inflammatory pain induced by formalin in rats.

Authors:  Xionggang Chen; Tingting Wang; Caizhu Lin; Baihong Chen
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 4.  Importance of sex to pain and its amelioration; relevance of spinal estrogens and its membrane receptors.

Authors:  Alan R Gintzler; Nai-Jiang Liu
Journal:  Front Neuroendocrinol       Date:  2012-10-02       Impact factor: 8.606

5.  Antagonists of the kappa-opioid receptor enhance allodynia in rats and mice after sciatic nerve ligation.

Authors:  I Obara; J Mika; M K-H Schafer; B Przewlocka
Journal:  Br J Pharmacol       Date:  2003-09-01       Impact factor: 8.739

6.  Opioid regulation of spinal cord plasticity: evidence the kappa-2 opioid receptor agonist GR89696 inhibits learning within the rat spinal cord.

Authors:  Stephanie N Washburn; Marissa L Maultsby; Denise A Puga; James W Grau
Journal:  Neurobiol Learn Mem       Date:  2007-11-05       Impact factor: 2.877

Review 7.  Pronociceptive actions of dynorphin via bradykinin receptors.

Authors:  Josephine Lai; Miaw-chyi Luo; Qingmin Chen; Frank Porreca
Journal:  Neurosci Lett       Date:  2008-04-08       Impact factor: 3.046

8.  Tyrosine phosphorylation of Kir3 following kappa-opioid receptor activation of p38 MAPK causes heterologous desensitization.

Authors:  Cecilea C Clayton; Mei Xu; Charles Chavkin
Journal:  J Biol Chem       Date:  2009-09-22       Impact factor: 5.157

9.  Neuropathic plasticity in the opioid and non-opioid actions of dynorphin A fragments and their interactions with bradykinin B2 receptors on neuronal activity in the rat spinal cord.

Authors:  Kirsty Bannister; Yeon Sun Lee; Leonor Goncalves; Frank Porreca; Josephine Lai; Anthony H Dickenson
Journal:  Neuropharmacology       Date:  2014-06-14       Impact factor: 5.250

Review 10.  The kappa-opiate receptor impacts the pathophysiology and behavior of substance use.

Authors:  David Mysels; Maria A Sullivan
Journal:  Am J Addict       Date:  2009 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.